- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01466855
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma (IARB1)
A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC).
The goals of this study are:
- To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery)
- To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC
- To assess visual pathway function before and after the study therapy
- To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 15 years of age or younger
- Diagnosis: Patients with untreated Group C/D/E unilateral Retinoblastoma at presentation without an indication for immediate enucleation (neovascular glaucoma or orbital pain) (Stratum A), or patients with a history of bilateral retinoblastoma and recurrent and/or refractory intraocular retinoblastoma where chemotherapy, external beam radiation and/or enucleation remain the only known option for disease control (Stratum B).
- Therapeutic Options: Chemotherapy, External Beam Radiation therapy and/or Enucleation
- Lansky ≥ 50 for patients ≤ 10 years of age; Karnofsky ≥ 50 for patients > 10 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Prior Therapy: Stratum A: No prior therapy is allowed. Stratum B: Patients must have local relapsed/refractory disease after receiving standard upfront therapy involving at least one chemotherapeutic regimen. There is no limit to prior chemotherapeutic regimens permitted. Prior radiation therapy is permitted.
Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, as described below:
- Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of study enrollment.
- Biologic therapies: Patients must not have received biologic anti-cancer agents within one week of study enrollment.
- Radiation therapy: Four weeks must have elapsed since external beam radiation therapy, if given.
Adequate Bone Marrow Function Defined as:
- Peripheral absolute neutrophil count (ANC) greater than or equal to 750/uL
- Platelet count greater than or equal to 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
- Hemoglobin greater than or equal to 8.0 gm/dL (may receive RBC transfusions)
Adequate Renal Function Defined as:
-Maximum serum creatinine based on age as follows: 1 to < 2 years- 0.6 mg/dL; 2 to < 6 years - 0.8 mg/dL; 6 to < 10 years- 1 mg/dL; 10 to < 13 years- 1.2 mg/dL; 13 to 15 years- 1.5 mg/dL for boys and 1.4 mg/dL for girls.
OR
Creatinine clearance or radioisotope GFR greater than or equal to 70ml/min/1.73 m2
Adequate Liver Function Defined As:
- Bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 x upper limit of normal (ULN) for age
- SGPT (ALT) less than or equal to 5 x upper limit of normal (ULN) for age
- Serum albumin greater than or equal to 2 g/dL
- Informed Consent: All patients and/or their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Patients of child-bearing potential must have a negative pregnancy test and agree to use an effective birth control method (abstinence is an acceptable form of birth control).
Exclusion Criteria:
- Extra-ocular retinoblastoma or retinoblastoma involving the anterior chamber
- Retinoblastoma that could otherwise be treated with laser therapy, cryotherapy, or plaque therapy only
- Structural brain abnormality
- Uncontrolled infection, defined as requiring intravenous antibiotics at the time of enrollment
Concomitant Medications
- Growth factors that support platelet or white cell number or function must not have been administered within 3 days prior to enrollment.
- Patients who are currently receiving non-FDA approved drugs, or who have received a non-FDA approved drug within 7 days prior to enrollment, are ineligible.
- Patients who are currently receiving other anti-cancer agents are ineligible.
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment of Retinoblastoma
Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
|
Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year event-free survival (event defined as the need for external beam radiation or enucleation)
Time Frame: 1 year
|
1 year
|
|
Response rate of retinoblastoma to topotecan when administered directly into the ophthalmic artery.
Time Frame: Up to 18 weeks
|
EUA and retCAM imaging will be used to assess response rate.
|
Up to 18 weeks
|
Local (ocular) toxicities associated with the proposed regimen. Toxicities assessed using clinical examinations (EUA and Teller cards and Allan figures or Snellen visual acuity charts or other measures as appropriate for child's age.)
Time Frame: Up to 12 months
|
|
Up to 12 months
|
Patterns of response of retinoblastoma to topotecan when administered directly into the ophthalmic artery.
Time Frame: Up to 18 weeks
|
Physical examination of the tumors will be recorded at baseline and at every tumor assessment visit.
Tumors will be classified as having Type I, II, III, IV, V or O response based on characteristic features identified during physical examination.
|
Up to 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual pathway function
Time Frame: Up to 12 months
|
Evaluation of visual pathway function will be measured using visual acuity, electroretinogram, visual evoked potential, and functional magnetic resonance imaging.
|
Up to 12 months
|
Pharmacokinetics (Cmax and AUC) of topotecan when administered directly into the ophthalmic artery.
Time Frame: Samples taken 15 and 60 minutes after topotecan administration on Day 1 of Cycle 1 (optional for patients)
|
Samples taken 15 and 60 minutes after topotecan administration on Day 1 of Cycle 1 (optional for patients)
|
|
Histologic findings in the eyes ultimately requiring enucleation.
Time Frame: At time of enucleation, only if indicated
|
Any eye requiring enucleation will be assessed for the presence or absence of 'high risk' features defined as scleral or massive choroidal invasion of viable tumor, anterior chamber involvement, invasion of the optic nerve posterior to the lamina cribrosa, ciliary body or iris invasion.
|
At time of enucleation, only if indicated
|
Collaborators and Investigators
Investigators
- Principal Investigator: James Geller, MD, Children's Hospital Medical Center, Cincinnati
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Retinal Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Eye Diseases, Hereditary
- Eye Neoplasms
- Retinal Neoplasms
- Retinoblastoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Topotecan
Other Study ID Numbers
- IARB1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinoblastoma
-
Children's Oncology GroupRecruitingBilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular Retinoblastoma | Recurrent Retinoblastoma | Extraocular RetinoblastomaUnited States, Canada, Puerto Rico
-
Children's Hospital Los AngelesRecruitingRetinoblastoma | Retinoblastoma Bilateral | Retinoblastoma UnilateralUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingCancer Survivor | Retinoblastoma | Unilateral Retinoblastoma | Intraocular Retinoblastoma | Biological SiblingUnited States, Canada
-
Amsterdam UMC, location VUmcRecruitingRetinoblastoma | Trilateral RetinoblastomaNetherlands
-
Memorial Sloan Kettering Cancer CenterRecruitingRetinoblastoma | Pediatric RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActive, not recruitingUnilateral RetinoblastomaArgentina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnilateral RetinoblastomaUnited States
Clinical Trials on Intra-Ophthalmic Artery Topotecan Infusion
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause | Amenorrhea | Infertility, Female | Anovulatory InfertilityGreece
-
Emory UniversityTexas Heart InstituteCompletedMyocardial Infarction | Coronary Artery DiseaseUnited States
-
Stanford UniversityWithdrawnRetinoblastoma | Eye CancerUnited States
-
Sandwell & West Birmingham Hospitals NHS TrustNot yet recruitingPre-Eclampsia | Fetal Growth Retardation
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingInfertility, Female | Perimenopausal Disorder | Menstrual Cycle AbnormalGreece
-
Yufang ShiSoochow UniversitySuspended
-
Royan InstituteCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Sun Yat-sen UniversityThird Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Imperial College LondonCompletedInfarction, Middle Cerebral Artery | Stroke, AcuteUnited Kingdom
-
Hospital Universitario Central de AsturiasHospitales Universitarios Virgen del RocíoCompletedInfarction, Middle Cerebral Artery | Stroke, AcuteSpain